News

Paragonix to Participate in 23rd Annual Needham Growth Conference in 2021 CAMBRIDGE, MASSACHUSETTS, January 4, 2020 — Paragonix Technologies, the leading hypothermic cardiothoracic organ preservation

Paragonix SherpaPak™ Cardiac Transport System provides its pioneering technology for transplant surgeons at first West Coast location CAMBRIDGE, MASSACHUSETTS, September 28, 2020- Paragonix Technologies announced

CAMBRIDGE, MASSACHUSETTS, July 20, 2020- Paragonix Technologies, Inc. today announced that its flagship product, Paragonix SherpaPak™ Cardiac Transport System (CTS), is the recipient of a

New data on successful transplantations for high-risk profile donor hearts presented at the American Transplant Congress CAMBRIDGE, MASSACHUSETTS, July 6, 2020- Paragonix Technologies, Inc. announced

Paragonix expands board to support rapid commercial growth in the heart transplant market CAMBRIDGE, MASSACHUSETTS, June 22, 2020- Paragonix Technologies, Inc. a commercial stage company

The Paragonix GUARDIAN Registry has reached its 100th patient enrollment milestone CAMBRIDGE, MASSACHUSETTS, June 2, 2020- Paragonix Technologies, Inc. today announced that its clinical global

Paragonix SherpaPak™ Cardiac Transport System is the only FDA cleared and CE marked device that safeguards hearts between donor and recipient patients CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies Inc.today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation

Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children’s Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.

Paragonix Technologies, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Paragonix SherpaPak™ Pancreas Transport System (PTS). Starting immediately, the Paragonix SherpaPak™ PTS will be commercially available to pancreas transplant centers and Organ Procurement Organizations. The Paragonix SherpaPak PTS provides unprecedented thermal and physical protection to the donor pancreas during transport from donor to recipient patients.

DURHAM, N.C.–(BUSINESS WIRE)-Duke University Hospital has transported its first donor heart using the only commercially available FDA cleared and CE marked system for cold donor

Paragonix Technologies is happy to announce that we will be sponsoring pet therapy at the University of Florida! Pet therapy can go a long way